Tetra Bio-Pharma and Ovensa collaborate to find treatment for Glioblastoma multiforme, the most common and deadliest brain tumors
Tetra Bio-Pharma Inc. recently announced that it has entered into a collaboration agreement with Ovensa Inc. to evaluate TRIOZAN™, a proprietary nanomedicine platform for targeted delivery of cannabinoids to brain tumor cells.
Glioblastoma multiforme (GBM) is the most common and most malignant of the glial tumors with a five-year survival rate lower than 5 percent. Its incidence in most European and North American countries is approximately two to three new cases per 100,000 people per year. The tremendous unmet need in GBM is substantiated by the lack of treatment progress and improvement in overall survival in this indication over the last several years.
“Glioblastoma multiforme (GBM) is a common and fatal type of brain cancer and sadly took the lives of Senator John McCain and singer Gordon Downey. Our collaboration with Ovensa will evaluate if TRIOZANÔ allows a targeted delivery of cannabinoids to the brain tumor. There is some published evidence demonstrating the activity of cannabinoids on brain tumors. If successful this could provide an increased efficacy when this treatment is used as an adjunct to radiotherapy and or chemotherapy. This technology is also being investigated for the delivery of an antibody to the brain as part of a collaboration between Ovensa and Takeda Pharmaceutical. Our collaboration with Ovensa is part of our ongoing cancer research program,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma.
“Ovensa’s TRIOZANTM Delivery Platform allows a high engineering flexibility where personalized nanomedicines are designed according to various parameters such as pathology, gene and molecular profile, cell targeting, type of payload, route of administration and multi-combination. The current collaboration is aimed at engineering a targeted Glioblastoma Dual-Cannabinoid TRIOZANTM-based therapeutic to achieve synergistic effects with therapeutic tools such as chemotherapy, radiotherapy and immunotherapy”, said Ovensa’s President and CEO, Stéphane Gagné.
Want to keep up to date on what’s happening in the world of cannabis? Subscribe to the Cannabis Post newsletter for weekly insights into the industry, what insiders will be talking about and content from across the Postmedia Network.